Advertisement Debiopharm, Ascenta sign licensing deal to develop AT-406 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Debiopharm, Ascenta sign licensing deal to develop AT-406

Debiopharm Group and Ascenta Therapeutics have partnered to develop and commercialize AT-406 (called Debio 1143 by Debiopharm).

AT-406 is an orally available small molecule helps in neutralizing major inhibitors of apoptosis and is anticipated to be effective in treating cancers in conjunction with anti-cancer therapies.

AT-406 can induce cancer cell death and/or potentiate the efficacy of other treatments.

Debiopharm President and Founder Rolland-Yves Mauvernay said it should be possible to combine AT-406 (or Debio 1143) with other pro-apoptotic agents, which can potentially bring benefits to patients by enhancing the efficiency of the treatment.